Infinium Global Research Biosimilar Monoclonal Antibodies Market | Page 2

A latest report has been added to the wide database of Biosimilar Monoclonal Antibodies Market by Infinium Global
Research. This report studies the Biosimilar Monoclonal Antibodies Market by drug class (rituximab, infliximab, abciximab,
trastuzumab, adalimumab, bevacizumab), application (oncology, chronic, auto immune diseases, growth hormone deficiency,
infectious diseases) market status and outlook of global and major regions, from manufacturers, and end industries. The
objective of the study is to identify market sizes of different segments & countries in recent years and to forecast the values
for the next six years. Biosimilar Monoclonal Antibodies Market provides opportunities in micro markets for stakeholders to
invest along with the detailed analysis of competitive landscape, latest trends, and product offerings of the major companies
in the Biosimilar Monoclonal Antibodies Market. The global biosimilar monoclonal antibodies market is projected to grow
with a CAGR of 42.8% over the period of 2017-2023 and reach USD 8.97 billion by 2023.
In 2016, the size of the global biosimilar monoclonal antibodies market was valued over USD 728.6 million. The global
biosimilar monoclonal antibodies market is projected to grow with a CAGR of 42.8% over the period of 2017-2023 and reach
USD 8.97 billion by 2023. Patent expiration of biologics, innovative product in the pipeline and increasing healthcare
infrastructure are expected to be key factors driving the growth of global biosimilar monoclonal antibodies market.
Moreover, rising demand for biosimilar drugs owing to their cost effectiveness is expected to inflate the market size of
biosimilar drugs over the forecast period. However, unfavorable government regulations and development policies,
undesirable manufacturing process and cost structure associated with the manufacturing process are considered to be
restraining factors in the global biosimilar monoclonal antibodies market. Furthermore, increasing demand for cost effective
treatment, collaboration with the local players and high profitability in the market are the key opportunities for the
companies to invest in the biosimilar monoclonal antibodies market.
Segments Covered:
The report segments the global biosimilar monoclonal antibodies market by drug class and by application. The biosimilar
monoclonal antibodies market is driven by rituximab and infliximab submarkets, the rituximab submarket is accounted as the
highest holding market share submarket and the infliximab submarket is likely to be the second largest segment over the
forecast period. The market segmentation based on drug class includes, rituximab, infliximab, abciximab, trastuzumab,
adalimumab, and bevacizumab. Moreover, based on application the biosimilar monoclonal antibodies market is segmented
into oncology, chronic and auto immune diseases, growth hormone deficiency and infectious diseases. The oncology
segment accounted for the largest market share in 2016 accounting for USD 393.9 million.
Infinium Global Research